DDIT3 and diffuse large B-cell lymphoma: The presence of these mutations in a GCB DLBCL and the association of GCB type with superior response to first line R-CHOP therapy supports the somewhat obvious notion that different (dysregulated) pathways respond differently, or not at all, to a given treatment.